GlassScriptPhysician profile
Alan Bruce Cohen
NPI 1265461842
$11,552.56
in general payments reported to CMS, 2019-2025
43 companies · $2,708 in 2025
The $2,708 reported for 2025 was more than what 81% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,700 · 2020: $582 · 2021: $91.83 · 2022: $1,143 · 2023: $2,375 · 2024: $1,952 · 2025: $2,708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,779 · Education: $256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,779.27 |
| Education | $256.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,474.09 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,972.14 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $845.55 | 2019-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $685.37 | 2019-2024 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Genzyme Corporation | $645.38 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $526.78 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Insmed, INC. | $482.31 | 2019-2025 | Arikayce, Brinsupri |
| Takeda Pharmaceuticals U.S.A., INC. | $369.42 | 2020-2025 | Glassia, Cuvitru, Hyqvia |
| Grifols USA, LLC | $361.94 | 2019-2025 | Prolastin-C Liquid, Xembify |
| United Therapeutics Corporation | $291.64 | 2019-2025 | Tyvaso, Tyvaso |
| Merck Sharp & Dohme LLC | $276.66 | 2019-2025 | Zerbaxa, Keytruda, Winrevair |
| Shire North American Group INC | $215.88 | 2019 | |
| Novartis Pharmaceuticals Corporation | $166.49 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $158.53 | 2022-2023 | Acthar |
| Amgen INC. | $155.96 | 2022-2025 | Tezspire |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $154.94 | 2019-2024 | Yupelri |
| Verona Pharma, INC. | $149.41 | 2025 | Ohtuvayre |
| Genentech USA, INC. | $147.85 | 2019-2025 | Xolair |
| Sunovion Pharmaceuticals INC. | $142.46 | 2019-2020 | |
| Philips North America LLC | $122.67 | 2019-2023 | |
| Vifor Pharma, INC. | $108.83 | 2024-2025 | Zemaira, Veltassa |
| Paratek Pharmaceuticals, INC. | $102.88 | 2022-2024 | Nuzyra |
| Viatris Specialty LLC | $97.57 | 2025 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $87.31 | 2019-2023 | |
| Abbvie INC. | $82.25 | 2023 | Teflaro, Avycaz |
| Sanofi-Aventis U.S. LLC | $74.75 | 2023 | |
| Baxter Healthcare | $71.18 | 2023-2024 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care, Hillrom - Monarch Airway Clearance System |
| Pfizer INC. | $69.77 | 2023 | |
| Electromed, INC. | $67.64 | 2024-2025 | Smartvest |
| Abbott Laboratories | $58.87 | 2024-2025 | Freestyle Libre 3, Aveir |
| Fisher & Paykel Healthcare INC | $49.46 | 2023 | Fisher & Paykel Healthcare |
| Allergan, INC. | $47.64 | 2019-2020 | |
| Circassia INC. | $45.78 | 2019 | |
| Jazz Pharmaceuticals INC. | $36.04 | 2020 | |
| Astellas Pharma US INC | $31.95 | 2019-2020 | |
| Inogen, INC. | $31.08 | 2025 | |
| Axsome Therapeutics, INC. | $29.82 | 2023 | Sunosi |
| Csl Behring | $26.81 | 2025 | Hizentra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.00 | 2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $20.45 | 2022 | |
| Alexion Pharmaceuticals, INC. | $17.93 | 2019 | |
| Nabriva Therapeutics, Plc | $14.33 | 2020 | |
| Tactile Systems Technology INC | $13.75 | 2025 | Nimbl, Flexitouch Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.